Lunsayil LTE: Extension study to evaluate long-term treatment with espesolimab in patients with hidradenitis suppurativa (HS).

CLINICAL TRIAL WITH MEDICINES

Home · Ee11-Immune-mediated Skin Diseases (Emerging)

Clinical trial information

Promoter: BOEHRINGER INGELHEIM ESPAÑA, SA
Phase: II
Execution start: 30/04/2024
End of execution: 30/09/2030
PI: RICARDO RUIZ VILLAVERDE